Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference. Fox News Media; ...

Additionally, an exploratory analysis showed semaglutide's near-halving of risk of combined rescue therapy or all-cause death (4% vs 8%, HR 0.46, 95% CI 0.24-0.85), as highlighted by Eugenia ...

- Topline data from the combination clinical study are expected in the fourth quarter of 2025. HONG KONG, May 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces that ...

At four weeks, semaglutide participants had an average difference in body weight of 1.1% lower than those in the placebo group. At 12 weeks, the average weight difference was 3.6% lower in the ...

Over the course of 72 weeks, people on tirzepatide lost an average of 20.2% of their body weight, or about 50 pounds. Those on semaglutide lost 13.7%, around 33 pounds.

This article highlights the first head-to-head study comparing two popular injectable weight-loss medications, semaglutide (Wegovy) and tirzepatide (Zepbound). Conducted by Weill Cornell Medicine ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

Treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist started with 0.25 mg weekly then escalated every 4 weeks to once-weekly doses of 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg—adjusting ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

How Much Weight Can You Lose on Semaglutide? The amount of weight you can lose on semaglutide varies from person to person. It’s based on numerous factors, like genetics, how your body reacts to ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

FRIDAY, May 2, 2025 (HealthDay News) -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes ...